<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0902210504
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Fosaprepitant SPC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FOSAPREPITANT DIMEGLUMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AD12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fosaprepitant SPC 150mg/Vial for Injection contains the active substance fosaprepitant which is converted to aprepitant in your body. It belongs to a group of medicines called &quot;neurokinin 1 (NK1) receptor antagonists&quot;. The brain has a specific area that controls nausea and vomiting.</p><p>Fosaprepitant SPC 150mg/Vial for Injection works by blocking signals to that area, thereby reducing nausea and vomiting. Fosaprepitant SPC 150mg/Vial for Injection is used in adults, adolescents, and children aged 6 months or older in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that is a strong or moderate trigger of nausea and vomiting.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Fosaprepitant SPC 150mg/Vial</strong> <strong>for Injection:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to fosaprepitant, aprepitant, or to polysorbate 80 or any of the other ingredients (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems).</p><p>Tell your doctor if you are taking these medicines since your treatment must be modified before you start using Fosaprepitant SPC 150mg/Vial for Injection.</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist, or nurse before using Fosaprepitant SPC 150mg/Vial for Injection.</p><p>Before treatment with Fosaprepitant SPC 150mg/Vial for Injection, tell your doctor if you have liver disease because your liver is important in breaking down the medicine in your body.</p><p>Your doctor may therefore have to monitor the condition of your liver.</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Do not give Fosaprepitant SPC 150mg/Vial for Injection to children under 6 months of age or who weigh less than 6 kg, because it has not been studied in this population.</p><p><strong>Other medicines and Fosaprepitant SPC 150mg/Vial</strong> <strong>for Injection</strong></p><p>&nbsp;</p><p>Fosaprepitant SPC 150mg/Vial for Injection can affect other medicines both during and after treatment with Fosaprepitant SPC 150mg/Vial for Injection There are some medicines that should not be taken with Fosaprepitant 150 mg/ Vial for Injection (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also &lsquo;Do not use Fosaprepitant SPC 150mg/Vial for Injection&rsquo;).</p><p>The effects of Fosaprepitant SPC 150mg/Vial for Injection or other medicines might be influenced if you take Fosaprepitant SPC 150mg/Vial for Injection together with other medicines including those listed below. Please talk to your doctor or pharmacist if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with Fosaprepitant SPC 150mg/Vial for Injection. Another or additional non-hormonal form of birth control should be used during treatment with Fosaprepitant SPC 150mg/Vial for Injection and for up to 2 months after using Fosaprepitant SPC 150mg/Vial for Injection, cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alfentanil, fentanyl (used to treat pain),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinidine (used to treat an irregular heart beat),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin, acenocoumarol (blood thinners; blood tests may be required),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin (a medicine used to treat seizures),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine (used to treat depression and epilepsy),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (an herbal preparation used to treat depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; protease inhibitors (used to treat HIV infections),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole except shampoo (used to treat Cushing&rsquo;s syndrome &ndash; when the body produces an excess of cortisol),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole, voriconazole, posaconazole (antifungals),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone (used to treat depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem (a medicine used to treat high blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids (such as dexamethasone),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-anxiety medicines (such as alprazolam),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolbutamide (a medicine used to treat diabetes)</p><p>Tell your doctor about any other medicines or herbal medicines you are taking, have recently taken, or might take.</p><p>Pregnancy and breast-feeding</p><p><strong>&nbsp;</strong></p><p>This medicine should not be used during pregnancy unless clearly necessary. If you are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine.</p><p>For information regarding birth control, see &lsquo;Other medicines and Fosaprepitant SPC 150mg/Vial for Injection&rsquo;.</p><p>It is not known whether Fosaprepitant SPC 150mg/Vial for Injection is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine. It is important to tell your doctor if you are breastfeeding or are planning to breast-feed before receiving this medicine.</p><p>Driving and using machines</p><p><strong>&nbsp;</strong></p><p>It should be taken into account that some people get dizzy and get sleepy after using Fosaprepitant SPC 150mg/Vial for Injection If you get dizzy or get sleepy, you should avoid driving or using machines after using Fosaprepitant SPC 150mg/Vial for Injection (see &lsquo;Possible side effects&rsquo;).</p><p><strong><u>Fosaprepitant SPC 150mg/Vial</u></strong><strong> <u>for Injection contains sodium</u></strong></p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>In adults (18 years of age and older), the recommended dose of Fosaprepitant SPC 150mg/Vial for Injection is 150 mg fosaprepitant on Day 1 (day of chemotherapy).</p><p>In children and adolescents (6 months to 17 years of age), the recommended dose of Fosaprepitant SPC 150mg/Vial for Injection is based on the patient&rsquo;s age and weight.</p><p>Depending on the chemotherapy treatment, there are two ways Fosaprepitant SPC 150mg/Vial for Injection may be given:</p><p>Fosaprepitant SPC 150mg/Vial for Injection is given only on Day 1 (single day of chemotherapy)</p><p>Fosaprepitant SPC 150mg/Vial for Injection is given on Day 1, 2, and 3 (single or multiple days of chemotherapy) Oral formulations of aprepitant may be prescribed on Days 2 and 3 instead of Fosaprepitant SPC 150mg/Vial for Injection.</p><p>The powder is reconstituted and diluted before use. The solution for infusion is given to you by a health care professional, such as a doctor or nurse, via an intravenous infusion (a drip) approximately 30 minutes before you start your chemotherapy treatment. Your doctor will ask you to take other medicines including a corticosteroid (such as dexamethasone) and a &lsquo;5HT3 antagonist&rsquo; (such as ondansetron) for preventing nausea and vomiting. Check with your doctor or pharmacist if you are not sure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking Fosaprepitant SPC 150mg/Vial for Injection and see a doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives, rash, itching, difficulty breathing or swallowing, or a serious decrease of blood pressure</p><p>(frequency not known, cannot be estimated from the available data); these are signs of a serious allergic reaction.</p><p>Other side effects that have been reported are listed below.</p><p><strong>Common side effects (may affect up to 1 in 10 people) are:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, indigestion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased amount of liver enzymes in your blood.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people) are:</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, sleepiness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne, rash,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiousness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased painful or burning urination,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness, generally feeling unwell,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddening of the face/skin, hot flush,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or irregular heartbeats, blood pressure increased,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever with increased risk of infection, lowering of red blood cells,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion site pain, infusion-site redness, infusion-site itching, infusion site vein inflammation.</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people) are:</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty thinking, lack of energy, taste disturbance,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity of the skin to sun, excessive sweating, oily skin, sores on skin, itching rash, Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; euphoria (feeling of extreme happiness), disorientation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection, fungal infection, severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequent urination, passing more urine than normal, presence of sugar or blood in urine,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort, swelling, change in the manner of walking,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, mucus in back of throat, throat irritation, sneezing, sore throat,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye discharge and itching,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ear,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, muscle weakness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heartbeat, heart and blood vessel disease,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lowering of white blood cells, low sodium levels in the blood, weight loss,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hardening of site of infusion.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The first 2 numbers indicate the month; the next 4 numbers indicate the year.</p><p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>The reconstituted and diluted solution is stable for 24 hours at 25&deg;C.</p><p>Do not throw away any medicines via wastewater or house hold waste.</p><p>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is fosaprepitant. Each vial contains fosaprepitant dimeglumine equivalent to 150 mg fosaprepitant.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: Disodium edetate, Polysorbate 80, Lactose anhydrous, Sodium hydroxide Pellets, Hydrochloric acid and Water for Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fosaprepitant SPC 150mg/Vial for Injection is a white to off-white lyophilized cake or powder for solution for infusion.
The powder is contained in a 10 mL Type-1 clear tubular glass vial with 13 mm neck containing Fosaprepitant Dimeglumine for Injection 150 mg/ vial in lyophilized cake or powder form is stoppered with 13 mm Bromo butyl double slotted rubber stopper sealed with 13 mm aluminium flip off seal with Green color plastic disc.
Each vial contains 150 mg of fosaprepitant. 
Pack sizes: 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer</strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia</p><p>Tel: +966-11 92000 1432</p><p>Fax: +966-11 4668195</p><p>Email: info@sudairpharma.com</p><p>Mailing: P.O. Box 19047 Riyadh, Saudi Arabia<em>.</em></p><p><strong>Manufacturer</strong></p><p>MSN LABORATORIES PRIVATE LIMITED</p><p>Formulations Division, Unit-II, Survey Nos. 1277, 1319 to 1324, Nandigama (Village &amp; Mandal), Rangareddy District, Telangana 509228, India<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 May. 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن على المادة الفعّالة فوسابريبيتانت التي يتم تحويلها داخل الجسم إلى أبريبيتانت. ينتمي فوسابريبيتانت اس بى سي إلى مجموعة من الأدوية التي تُسمى باسم &quot;مناهضات مستقبلات النيوروكينين 1&quot;(NK1). توجد منطقة محددة في المخ مسئولة عن الغثيان والقيء.</p><p dir="RTL">يعمل فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن عن طريق منع وصول الإشارات إلى تلك المنطقة، وذلك يعمل على تقليل الغثيان والقيء. يُستخدم فوسابريبيتانت اس بى سي 150 مجم/زجاجة للحقن في المرضى من البالغين والمراهقين والأطفال الذين تصل أعمارهم 6 أشهر أو أكثر بمصاحبة أدوية أخرى لمنع الغثيان والقيء الناجمان عن العلاج الكيميائي (علاج السرطان) الذي يٌعد محفزًا قويا أو متوسطًا للغثيان والقيء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن في الحالات التَّالية:</p><ul dir="rtl"><li>إذا كنت تعاني من حساسية تجاه فوسابريبيتانت أو أبريبيتانت أو بوليسوربات 80 أو أيٍّ مكون من المكونات الأخرى الداخلة في تركيب هذا الدواء (المدرجة في القسم رقم 6).</li><li>مع الأدوية التي تحتوي على بيموزيد (أدوية تُستخدم لعلاج الأمراض النفسية) وتيرفينادين وأستيميزول (يُستخدمان لعلاج حمّى القش وحالات الحساسية الأخرى) وسيسابرايد (يُستخدم لعلاج اضطرابات الجهاز الهضمي). يُرجى إبلاغ الطبيب المعالج لك إذا كنت تستخدم هذه الأدوية قبل البدء في استخدام فوسابريبيتانت ديميجلومين اس بى سي150 مجم/زجاجة للحقن لتعديل جرعات العلاج الخاص بك.</li></ul><p dir="RTL"><strong><u>تحذيرات واحتياطات</u></strong></p><p dir="RTL">تحدَّث إلى الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة) المتابع (ة) لحالتك قبل استخدام فوسابريبيتانت ديميجلومين اس بى سي.</p><p dir="RTL">يُرجى إبلاغ الطبيب المعالج لك، قبل بدء العلاج باستخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن، إذا كنت تعاني من مرض كبدي لإن الكبد هو المسئول عن تكسير هذا المنتج الدوائي داخل الجسم. لذلك يتعيّن على الطبيب المعالج لك متابعة حالة الكبد التي تعاني منها.</p><p dir="RTL"><strong><u>المرضى من الأطفال والمراهقين</u></strong></p><p dir="RTL">لا يُنصح باستخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن في المرضى من الأطفال الذين تقل أعمارهم عن ستة أشهر أو الذين يكون وزنهم أقل من 6 كجم؛ لا توجد دراسات تثبت استخدامه في هذه الفئة العمرية.</p><p dir="RTL"><strong><u>استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن مع الأدوية الأخرى </u></strong></p><p dir="RTL">من الممكن أن يؤثر فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن على فعالية أدوية أخرى أثناء وبعد العلاج بفوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن. يجب ألا يتم استخدام بعض الأدوية بالتزامن مع فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن (مثل بيموزيد وتيرفينادين وأستيميزول وسيسابرايد) أو الأدوية التي تستلزم تعديل الجرعة (انظر أيضًا &quot;لا تقمْ باستخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن في الحالات التالية&quot;).</p><p dir="RTL">من المحتمل أن تؤثر بعض الأدوية على فعالية فوسابريبيتانت اس بى سي إذا استخدمت بالتزامن معه بما في ذلك الأدوية المُدرجة فيما بعد. يُرجى التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تستخدم أيًّا من الأدوية التَّالية:</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية منع الحمل التي يمكن أن تشتمل على حبوب منع الحمل واللصقات الجلدية وشرائح منع الحمل المزروعة وبعض أنواع اللولب الرحمي (IUDs) حيث تفرز هرمونات؛ ولذلك قد تتأثر فعالية تلك الأدوية عند استخدامها بالتزامن مع فوسابريبيتانت ديميجلومين اس بى سي. ينبغي أن يتم استخدام نوع آخر أو إضافي من أدوية منع الحمل غير الهرمونية أثناء العلاج باستخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن ولمدة زمنية تصل إلى شهرين بعد استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن.</p><p dir="RTL">سيكلوسبورين، تاكروليموس، سيروليموس، إيفيروليموس (أدوية مثبطة للمناعة)،</p><ul dir="rtl"><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل، فينتانيل (أدوية تستخدم لعلاج الآلام)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (دواء يستخدم لعلاج عدم انتظام ضربات القلب)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيرينوتيكان، إيتوبوسايد، فينورلبين، إيفوسفاميد (أدوية تستخدم لعلاج السرطان)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تحتوي على مشتقات قلويدات الأرجوت مثل إيرجوتامين وداي-إيرجوتامين (يُستخدمان لعلاج الصداع النصفي)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين، أسينوكومارول (أدوية تستخدم لمنع تخثّر الدم والجلطات الدموية؛ قد يتطلب إجراء فحوصات دم)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، كلاريثرومايسين، تيليثرومايسين (مُضادات حيوية تُستخدم لعلاج حالات العدوى)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (دواء يُستخدم لعلاج النوبات التشنجية)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كربامازِيبين (دواء يُستخدم لعلاج الاكتئاب ونوبات الصرع)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميدازولام، تريازولام، فينوباربيتال (أدوية تُستخدم كمهدئات ولتساعدك على النوم)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (مستحضر من الأعشاب يُستخدم لعلاج الاكتئاب)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إنزيم البروتياز (أدوية تُستخدم لعلاج حالات العدوى بفيروس نقص المناعة المٌكتسب&ldquo;HIV&rdquo;)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول باستثناء الموجود بالشامبو (دواء يُستخدم في علاج مرض متلازمة كوشينج &ndash; عندما يقوم الجسم بإنتاج كمية كبيرة من هرمون الكورتيزول)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتراكونازول، فوريكونازول، پوساکونازول (أدوية تُستخدم كمضادات للفطريات)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (دواء يُستخدَم في علاج الاكتئاب)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ديلتيازيم (دواء يُستخدم لعلاج ارتفاع ضغط الدم)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كورتيكوستيرويدات (مثل ديكساميثازون)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادّة للقلق (مثل ألبرازولام)،</li><li>&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولبوتاميد (دواء يُستَخدَم لعلاج مرض السُّكَّرِي)</li></ul><p dir="RTL">يُرجى إبلاغ الطبيب المعالج لك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّ أدوية أخرى أو مستحضرات عشبية.</p><p dir="RTL"><strong><u>الحمل والرضاعة الطبيعية</u></strong></p><p dir="RTL">يجب عدم استخدام هذا الدواء أثناء فترة الحمل ما لم تكن هناك ضرورة واضحة لذلك. استشيري الطبيب المعالج لكٍ قبل استخدام هذا الدَّواء إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للإنجاب.</p><p dir="RTL">للتعرف على المزيد من المعلومات حول وسائل منع الحمل، انظر قسم &quot;استخدام أدوية أخرى بالتزامن مع فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن&quot;.</p><p dir="RTL">من غير المعروف ما إذا كان فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن يُفرَز في لبن الأم أم لا؛ لذلك لا ينصح بممارسة الرضاعة الطبيعية أثناء العلاج باستخدام هذا الدَّواء. ومن المهم إبلاغ الطبيب المعالج لكٍ إذا كنتِ تُمارسين الرضاعة الطبيعية أو تخططين لممارسة الرضاعة الطبيعية قبل بدء العلاج باستخدام هذا الدواء.</p><p><u>القيادة واستخدام الآلات</u></p><p dir="RTL">يجب وضع في الاعتبار أنه قد يشعر بعض المرضى بالدوخة والنعاس بعد استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن؛ فإذا شعرت بدوخة أو نعاس بعد استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن، ينبغي عليك تجنب القيادة أو استخدام الآلات (انظر &quot;الآثار الجانبية المُحتملة&quot;).</p><p dir="RTL">يحتوي فوسابريبيتانت اس بى سي150 مجم/ زجاجة للحقن على الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل جرعة، مما يعني أن العقار &quot;شبه خال من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة الموصي بها من فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن للمرضى من البالغين (الذين تبلغ أعمارهم 18 عامًا وأكثر) هي 150 مجم من فوسابريبيتانت في اليوم الأول (من العلاج الكيميائي).</p><p dir="RTL">يتم تحديد الجرعة الموصي بها من فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن للمرضى من الأطفال والمراهقين (الذين تتراوح أعمارهم ما بين 6 أشهر و17 عامًا) حسب عمر ووزن المريض. بناء على العلاج الكيميائي، يوجد هناك طريقتان يمكن من خلالها استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن على النحو التالي:</p><ul dir="rtl"><li>يٌستخدم فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن في اليوم الأول فقط (يوم واحد من العلاج الكيميائي).</li><li>يٌستخدم فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن في اليوم الأول والثاني والثالث (يوم واحد أو أيام متعددة من العلاج الكيميائي).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم وصف تركيبات دوائية من أبريبيتانت للتناول عن طريق الفم في اليوم الثاني والثالث بدلاً من استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن.</p><p dir="RTL">يتم تحضير وتخفيف المسحوق قبل الاستخدام. سيقوم أخصائي الرعاية الصحية، مثل الطبيب المعالج لك أو الممرض (ة) المتابع(ة) لك، بإعطائك المحلول المٌعد للتسريب داخل الوريد (بالتنقيط) قبل بدء العلاج الكيميائي بـ 30 دقيقة تقريبًا. سيقوم الطبيب المعالج لك بإعطائك بعض الأدوية الأخرى: كورتيكوستيرويد (مثل ديكساميثازون) و&quot;مضادات مستقبلات هيدروكسي تريبتامين أو السيروتونين (5HT3)&quot; (مثل أوندانسيترون) لمنع حدوث غثيان وقيء. استشر الطبيب المعالج لك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبّب هذا الدواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لدى جميع المرضى.</p><p dir="RTL"><strong><u>يجب عليك التوقف عن استخدام فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن و</u></strong><strong><u>استشر ال</u></strong><strong><u>طبيب المعالج لك على الفور، إذا لاحظت أيٍّ من الآثار الجانبية التالية، والتي قد تكون خطيرة وتتطلب علاج طبي عاجل:</u></strong></p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; شرى (ارتكاريا) أو طفح جلدي أو حكة أو صعوبة في التنفس أو البلع أو انخفاض شديد في ضغط الدم (آثار جانبية غير معروف معدّل تكرارها (لا يمكن تقدير معدّل تكرارها من واقع البيانات المتاحة)؛ تكون تلك الآثار علامات لوجود تفاعلات تحسسية شديدة.</p><p dir="RTL">يتم إدراج الآثار الجانبية الأخرى التي تم الإبلاغ عنها فيما يلي.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى) تشمل ما يلي:</u></strong></p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; &nbsp;إمساك، عسر هضم،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; صداع،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; تعب،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; فقدان الشهية،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; نوبات الفُواق (زوغطة أو حازوقة)،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات الكبد في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض) تشمل ما يلي:</u></strong></p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; دوخة، شعور بالنعاس،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; حبّ الشباب، طفح جلدي،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; شعور بالقلق،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; تجشؤ (تنفس المعدة وإحداثها صوتًا)، غثيان، قيء، حموضة معوية (حُرْقَةُ في فم المعدة)، ألم بالمعدة، جفاف الفَم، خروج ريح،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; الشعور بألم متزايد أو حرقان أثناء التبول،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; &nbsp;ضعف، شعور عام بالإعياء (توعُّك)</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; احمرار الوجه/ الجلد، هبّات ساخنة (شعور مفاجئ بالحرارة يمتد عبر الجزء العلوي من الجسم والوجه)،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; سرعة أو عدم انتظام ضربات القلب، ارتفاع ضغط الدم،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; حمّى مصحوبة بخطورة متزايدة لحدوث أيّة عدوى، انخفاض عدد خلايا الدم الحمراء،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; ألم أو احمرار أو حكّة بموضع الحقن الوريدي، التهاب وريدي بموضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 1.000 مريض) تشمل ما يلي:</u></strong></p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; صعوبة في التفكير، نقص وفقدان طاقة الجسم (وهن)، اضطراب حاسة التذوق،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; حساسية الجلد لأشعة الشمس، تعرّق زائد، بشرة دهنية، قُرح تظهر على الجلد، طفح جلدي مصحوب بحكة، متلازمة ستيفنز جونسون/تَقَشُّرُ الأَنْسِجَةِ المُتَمَوِّتَةِ التَّسَمُّمِيّ (تفاعلات جلدية شديدة ونادرة)</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; شعور بالنشاط والخفة، توهان،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; عدوى بكتيرية، عدوى فطرية، امساك شديد، قرحة المعدة، التهاب الأمعاء الدقيقة والقولون، قَرْحات بالفم، الشعور بانتفاخ.</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; التبوّل بشكل متكرر، التبوّل بكمية أكثر من المعتاد، وجود سكر أو دم في البول،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; ضيق بالصدر، تورّم، تغيّر بطريقة المشي،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; سعال، مخاط أو بلغم خلف الحلق، تهيّج واحتقان الحلق، عطس، قرح بالحلق،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; وجود افرازات من العين وحكّة.</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; طنين الأذن.</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; شدّ عضلي، ضعف العضلات،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; عطش زائد،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; بطء ضربات القلب، اضطرابات بالقلب والأوعية الدموية،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء، انخفاض مستويات الصوديوم في الدم، فقدان الوزن،</p><p dir="RTL">&mdash;&nbsp;&nbsp;&nbsp; تصلّب وتيبس موضع الحقن.</p><p><u>&nbsp;</u></p><p><u>الإبلاغ عن الآثار الجانبية</u></p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة) المتابع(ة) لحالتك. ويشمل هذا أيّة آثار جانبية مُحتَمَلة وغير مُدرجة في هذه النَّشرة. يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء من خلال إبلاغك عن الآثار الجانبية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدَّواء بعيدًا عن متناول ورؤية الأطفال.</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدوّن على العبوة الكرتونية والعبوة الزجاجية بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">يشير أول رقمين إلى الشهر؛ وتشير الأربعة أرقام التالية إلى السنة.</p><p dir="RTL">يتم تخزنه في درجة حرارة بين 2 الى 8 درجة مئوية</p><p dir="RTL">يُحفظ هذا الدواء في الثلاجة.</p><p dir="RTL">يكون المحلول المخفف والمعاد تركيبه مستقرًا وغير قابل للانحلال لمدة 24 ساعة عند درجة حرارة 25 درجة مئوية.</p><p dir="RTL">لا تقم بالتخلّص من الأدوية عن طريق إلقائها في مياه الصرف أو المخلّفات المنزلية. استشر الصيدلي الخاص بك حول كيفية التَّخلص من الأدوية التي لم تعد تحتاج إليها. حيث تساعد هذه التدابير في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>&nbsp;المادة الفعالة هي فوسابريبيتانت. تحتوي كل زجاجة على فوسابريبيتانت ديميجلومين بما يعادل 150 مجم من فوسابريبيتانت. يحتوي كل واحد مللي من المحلول على 1 مجم من فوسابريبيتانت (1 مجم / مللي لتر) بعد القيام بإعادة تركيبه وتخفيفه.</li><li>تشمل المكونات الأخرى ما يلي: إيدِيتات ثنائي الصوديوم وبوليسوربات 80 ولاكتوز لامائي وحُبيبات هيدروكسيد الصوديوم وحمض الهيدروكلوريك وماء للحقن</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوى فوسابريبيتانت اس بى سي150 مجم/زجاجة للحقن على مسحوق فى شكل قرص مجفف بالتجميد لونه أبيض يميل إلى الأصفر أو في شكل مسحوق حرلتحضير محلول للحقن الوريدى.</p><p dir="RTL">يكون المسحوق مُعبأ في عبوة أنبوبية زجاجية شفافة من النوع 1 وفقًا لدستور الأدوية الأمريكي USP -1 بسعة 10 مللي لتر، مُغلقة بسدادة مطاطية ذات شق مزدوج من مادة البرومو بوتيل بطول 13مم ومُحكمة الغلق بغطاء من مادة الألومنيوم لمنع التسريب بطول 30 مم.</p><p dir="RTL">تحتوي كل عبوة زجاجية على 150 مجم من فوسابريبيتانت.</p><p dir="RTL">&nbsp;<strong>أحجام العبو</strong><strong>ات</strong><strong>:</strong> 1 عبوة زجاجية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق</p><p dir="RTL">شركة سدير فارما (SPC)</p><p dir="RTL">طريق الملك فهد، مبنى رقم 911- الدوران الأول، الرياض، المملكة العربية السعودية.</p><p dir="RTL">هاتف : 920001432 &ndash; 11 - 00966</p><p dir="RTL">فاكس رقم:&nbsp; 4668195 &ndash; 11 - 00966</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL">عنوان المراسلة: صندوق بريد: 19047 الرياض، المملكة العربية السعودية</p><p>جهة التصنيع:</p><p dir="RTL">مختبرات إم إس إن الخاصة المحدودة</p><p dir="RTL">قسم التركيبات الصيدلانية، وحدة رقم 2، مناطق تقسيم رقم 1277، 1319 حتى 1324، نانديجاما، (فيلدج وماندال)،</p><p dir="RTL">منطقة رانجاريدي، تالينجانا 509228، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2019. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fosaprepitant SPC 150mg/Vial for Injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains Fosaprepitant Dimeglumine 245.3 mg Equivalent to 150 mg Fosaprepitant.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
White to off white lyophilized cake or powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.</p><p>Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusionis given as part of a combination therapy (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is 150 mg administered as an infusion <strong>over 20-30 minutes </strong>on Day 1, initiated approximately 30 minutes prior to chemotherapy (see section 6.6). Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusion should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in the tables below.</p><p>The following regimens are recommended for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.</p><table border="1" cellspacing="1" cellpadding="1" style="width:900px"><tbody><tr><td style="width:97px">&nbsp;</td><td style="width:186px"><strong>Day 1</strong></td><td><strong>Day 2</strong></td><td><strong>Day 3</strong></td><td><strong>Day 4</strong></td></tr><tr><td style="width:97px">Fosaprepitant SPC 150mg/Vial for Injection</td><td style="width:186px">150 mg intravenously</td><td>none</td><td>none</td><td>none</td></tr><tr><td style="width:97px">Dexamethasone</td><td style="width:186px">12 mg orally</td><td>8 mg orally</td><td>8 mg orally twice daily</td><td>8 mg orally twice daily</td></tr><tr><td style="width:97px">5-HT3 antagonists</td><td style="width:186px"><p>Standard dose of 5-HT3 antagonists.</p><p>See the product information for the selected 5-HT3 antagonist for appropriate dosing information</p></td><td>none</td><td>none</td><td>none</td></tr></tbody></table><p>&nbsp;</p><p><strong>Dexamethasone </strong>should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. Dexamethasone should also be administered in the evenings on Days 3 and 4. The dose of dexamethasone accounts for active substance interactions.</p><p><strong><em>Moderately Emetogenic Chemotherapy Regimen</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Day 1</strong></p></td></tr><tr><td><p>Fosaprepitant SPC 150mg/Vial for Injection</p></td><td><p>150 mg intravenously</p></td></tr><tr><td><p>Dexamethasone</p></td><td><p>12 mg orally</p></td></tr><tr><td><p>5-HT3 antagonists</p></td><td><p>Standard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for appropriate dosing information</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Dexamethasone </strong>should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for active substance interactions.</p><p><strong><em><u>Paediatric population</u></em></strong></p><p>Paediatric patients aged 6 months and older, and not less than 6 kg</p><p>The recommended dose regimen of Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusion, to be administered with a 5-HT3 antagonist, with or without a corticosteroid, for the prevention of nausea and vomiting associated with administration of single or multi-day chemotherapy regimens of Highly Emetogenic Chemotherapy (HEC) or Moderately Emetogenic Chemotherapy (MEC), is shown in Table 1. Single day chemotherapy regimens include those regimens in which HEC or MEC is administered for a single day only. Multi-day chemotherapy regimens include chemotherapy regimens in which HEC or MEC is administered for 2 or more days.</p><p>An alternative dose regimen that may be used with single-day chemotherapy regimens is shown in Table 2.</p><p>Dosing for Single or Multi-Day Chemotherapy Regimens For paediatric patients receiving single or multi-day regimens of HEC or MEC, administer Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusionas an intravenous infusion through a central venous catheter on Days 1, 2, and 3. Fosaprepitant dimeglumine capsules or Fosaprepitant dimeglumine for oral suspension may be used on Days 2 and 3 instead of Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusion, as shown in Table 1. See the Summary of Product Characteristics (SmPC) for Fosaprepitant dimeglumine capsules or Fosaprepitant dimeglumine for oral suspension for appropriate dosing instructions.</p><p>Table 1</p><p>Recommended dosing for the prevention of nausea and vomiting associated with single or multi-day regimens of HEC or MEC</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Population</p></td><td><p><strong>Day 1</strong></p></td><td><p><strong>Day 2</strong></p></td><td><p><strong>Day 3</strong></p></td></tr><tr><td><p>Fosaprepitant SPC 150mg/Vial for Injection</p></td><td><p>Paediatric patients 12 years and older</p></td><td><p>115 mg intravenously</p></td><td><p>80 mg intravenously OR</p><p>80 mg orally (Fosaprepitant dimeglumine capsules)</p></td><td><p>80 mg intravenously OR</p><p>80 mg orally (Fosaprepitant dimeglumine capsules)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Paediatric patients 6 months to less than 12</p><p>years and not less</p><p>than 6 kg</p></td><td><p>3 mg/kg intravenously Maximum dose 115 mg</p></td><td><p>2 mg/kg intravenously OR</p><p>2 mg/kg orally (Fosaprepitant dimeglumine oral suspension) Maximum dose 80 mg</p></td><td><p>2 mg/kg intravenously OR</p><p>2 mg/kg orally (Fosaprepitant dimeglumine oral suspension) Maximum dose 80 mg</p></td></tr><tr><td><p>Dexamethasone</p><p>**</p></td><td><p>All paediatric patients</p></td><td colspan="3"><p>If a corticosteroid, such as dexamethasone, is co-administered, administer 50% of the recommended corticosteroid dose on days&nbsp;&nbsp;&nbsp; 1 through 4</p></td></tr><tr><td><p>5-HT3</p><p>antagonists</p></td><td><p>All paediatric patients</p></td><td colspan="3"><p>See selected 5-HT3 antagonist prescribing information for the recommended dosage</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p>* For paediatric patients 12 years and older, administer Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusionintravenously over 30 minutes, completing the infusion approximately 30 minutes prior to chemotherapy. For paediatric patients less than 12 years, administer Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusionintravenously over 60 minutes, completing the infusion approximately 30 minutes prior to chemotherapy.</p><p>** Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. Alternative Dosing for Single Day Chemotherapy Regimens</p><p>For paediatric patients receiving single day HEC or MEC, Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusionmay be administered as an intravenous infusion through a central venous catheter on Day 1.</p><p><strong>Table 2</strong> Alternative dosing for the prevention of nausea and vomiting associated with single day regimens of HEC or MEC</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Population</strong></p></td><td><p><strong>Day 1</strong></p></td></tr><tr><td><p>Fosaprepitant SPC 150mg/Vial for Injection</p></td><td><p>Paediatric patients 12</p><p>years and older</p></td><td><p>150 mg intravenously</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Paediatric patients 2 to less than 12 years and not less than 6 kg</p></td><td><p>4 mg/kg intravenously Maximum dose 150 mg</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Paediatric patients 6 months to less than 2 years and not less than 6 kg</p></td><td><p>5 mg/kg intravenously Maximum dose 150 mg</p></td></tr><tr><td><p>Dexamethasone</p><p>**</p></td><td><p>All paediatric patients</p></td><td><p>If a corticosteroid, such as dexamethasone, is co- administered, administer 50% of the recommended corticosteroid dose on days 1 and 2</p></td></tr><tr><td><p>5-HT3</p><p>antagonists</p></td><td><p>All paediatric patients</p></td><td><p>See selected 5-HT3 antagonist prescribing information for the recommended dosage</p></td></tr></tbody></table><p>&nbsp;</p><p>* For paediatric patients 12 years and older, administer Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusion intravenously over 30 minutes, completing the infusion approximately 30 minutes prior to chemotherapy. For paediatric patients less than 12 years, administer Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusion intravenously over 60 minutes, completing the infusion approximately 30 minutes prior to chemotherapy.</p><p>** Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The safety and efficacy of Fosaprepitant SPC 150mg/Vial for Injection Powder for solution for infusion in infants below 6 months of age have not been established. No data are available.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>General</u></strong></p><p>Efficacy data in combination with other corticosteroids and 5-HT3 antagonists are limited. For additional information on the co-administration with corticosteroids, see section 4.5.</p><p>Refer to the Summary of Product Characteristics of co-administered 5-HT3 antagonist medicinal products.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Special populations</u></em></strong></p><p><em>Older people (&ge;65 years)</em></p><p>No dose adjustment is necessary for the elderly (see section 5.2).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Gender</u></em></strong></p><p>No dose adjustment is necessary based on gender (see section 5.2).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Renal impairment</u></em></strong></p><p>No dose adjustment is necessary for patients with renal impairment or for patients with end stage renal disease undergoing hemodialysis (see section 5.2).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Hepatic impairment</u></em></strong></p><p>No dose adjustment is necessary for patients with mild hepatic impairment. There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. Fosaprepitant for Injection 150 mg/ Vial for Injection should be used with caution in these patients (see sections 4.4 and 5.2).</p><p><strong><em><u>Method of administration</u></em></strong></p><p>Fosaprepitant SPC 150mg/Vial for Injection should be administered intravenously and should not be given by the intramuscular or subcutaneous route. Intravenous administration occurs preferably through a running intravenous infusion over 20-30 minutes.</p><p>Intravenous administration in paediatric patients aged 6 months and older is recommended through a central venous catheter and should be administered over 30 minutes in patients aged 12 years and older or over 60 minutes in patients less than 12 years of age (See section 6.6). Do not administer Fosaprepitant SPC 150mg/Vial for Injection a bolus injection or undiluted solution.</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to polysorbate 80 or any of the other excipients listed in section 6.1.
Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Patients with moderate to severe hepatic impairment</u></em></strong></p><p>There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. Fosaprepitant SPC 150mg/Vial for Injection should be used with caution in these patients (see section 5.2).</p><p>&nbsp;</p><p><strong><em><u>CYP3A4 interactions</u></em></strong></p><p>Fosaprepitant SPC 150mg/Vial for Injection should be used with caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5). Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.</p><p>&nbsp;</p><p><strong><em><u>Co-administration with warfarin (a CYP2C9 substrate)</u></em></strong></p><p>In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely for 14 days following the use of fosaprepitant (see section 4.5).</p><p>&nbsp;</p><p><strong><em><u>Co-administration with hormonal contraceptives</u></em></strong></p><p>The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant. Alternative non-hormonal back-up methods of contraception should be used during treatment with fosaprepitant and for 2 months following the use of fosaprepitant (see section 4.5).</p><p>&nbsp;</p><p><strong><em><u>Hypersensitivity reactions</u></em></strong></p><p>Isolated reports of immediate hypersensitivity reactions including flushing, erythema, dyspnoea and anaphylaxis/anaphylactic shock have occurred during infusion of fosaprepitant. These hypersensitivity reactions have generally responded to discontinuation of the infusion and administration of appropriate therapy. It is not recommended to reinitiate the infusion in patients who experience hypersensitivity reactions.</p><p>&nbsp;</p><p><strong><em><u>Administration and infusion site reactions</u></em></strong></p><p>Fosaprepitant SPC 150mg/Vial for Injection should not be given as a bolus injection, but should always be diluted and given as a slow intravenous infusion (see section 4.2). Fosaprepitant SPC 150mg/Vial for Injection should not be administered intramuscularly or subcutaneously (see section 5.3). Mild injection site thrombosis has been observed at higher doses. If signs or symptoms of local irritation occur, the injection or infusion should be terminated and restarted in another vein.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When administered intravenously fosaprepitant is rapidly converted to aprepitant.</p><p>&nbsp;</p><p>Fosaprepitant 150 mg, given as a single dose, is a weak inhibitor of CYP3A4. Fosaprepitant does not seem to interact with the P-glycoprotein transporter, as demonstrated by the lack of interaction of oral aprepitant with digoxin. It is anticipated that fosaprepitant would cause less or no greater induction of CYP2C9, CYP3A4 and glucuronidation than that caused by the administration of oral aprepitant. Data are lacking regarding effects on CYP2C8 and CYP2C19.</p><p>Interactions with other medicinal products following administration of intravenous fosaprepitant are likely to occur with active substances that interact with oral aprepitant. The potential for interactions with multi-day fosaprepitant regimens are anticipated to be no greater than those for oral aprepitant regimens. Therefore, the recommendations for use of Fosaprepitant SPC 150mg/Vial for Injection with other medicinal products in paediatric patients are based upon adult data from fosaprepitant and aprepitant studies. When using combined Fosaprepitant SPC 150mg/Vial for Injection and Fosaprepitant dimeglumine regimens, please refer to the Summary of Product Characteristics (SmPC) section 4.5 for Fosaprepitant dimeglumine capsules or Fosaprepitant dimeglumine for oral suspension.</p><p>The following information was derived from studies conducted with oral aprepitant and studies conducted with intravenous single-dose fosaprepitant co-administered with dexamethasone, midazolam, or diltiazem.</p><p>&nbsp;</p><p><strong><em><u>Effect of fosaprepitant on the pharmacokinetics of other active substances</u></em></strong></p><p><strong><em><u>CYP3A4 inhibition</u></em></strong></p><p>As a weak inhibitor of CYP3A4, the fosaprepitant 150 mg single dose can cause a transient increase in plasma concentrations of co-administered active substances that are metabolised through CYP3A4. The total exposure of CYP3A4 substrates may increase up to 2-fold on Days 1 and 2 after co- administration with a single 150 mg fosaprepitant dose. Fosaprepitant must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by fosaprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life- threatening reactions. (See section 4.3). Caution is advised during concomitant administration of fosaprepitant and active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see section 4.4).</p><p>&nbsp;</p><p><strong><em><u>Corticosteroids</u></em></strong></p><p>Dexamethasone<em>: </em>The oral dexamethasone dose should be reduced by approximately 50 % when co- administered with fosaprepitant (see section 4.2). Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC0-24hr of dexamethasone, a CYP3A4 substrate, by 100 % on Day 1, 86 % on Day 2 and 18 % on Day 3 when dexamethasone was co-administered as a single 8 mg oral dose on Days 1, 2, and 3.</p><p>&nbsp;</p><p><strong><em><u>Chemotherapeutic medicinal products</u></em></strong></p><p>Interaction studies with fosaprepitant 150 mg and chemotherapeutic medicinal products have not been conducted; however, based on studies with oral aprepitant and docetaxel and vinorelbine, Fosaprepitant for Injection 150 mg/ Vial is not expected to have a clinically relevant interaction with intravenously administered docetaxel and vinorelbine. An interaction with orally administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g. etoposide, vinorelbine) cannot be excluded. Caution is advised and additional monitoring may be appropriate in patients receiving medicinal products metabolised primarily or partly by CYP3A4 (see section 4.4). Post-marketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant and ifosfamide coadministration.</p><p>&nbsp;</p><p><strong><em><u>Immunosuppressants</u></em></strong></p><p>Following a single 150 mg fosaprepitant dose, a transient moderate increase for two days possibly followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g. cyclosporine, tacrolimus, everolimus and sirolimus) is expected. Given the short duration of increased exposure, dose reduction of the immunosuppressant based on Therapeutic Dose Monitoring is not recommended on the day of and the day after administration of Fosaprepitant SPC 150mg/Vial for Injection.</p><p>&nbsp;</p><p><strong><em><u>Midazolam</u></em></strong></p><p>Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC 0-&infin; of midazolam by 77 % on Day 1 and had no effect on Day 4 when midazolam was co-administered as a single oral dose of 2 mg on Days 1 and 4. Fosaprepitant 150 mg is a weak CYP3A4 inhibitor as a single dose on Day 1 with no evidence of inhibition or induction of CYP3A4 observed on Day 4.</p><p>The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with Fosaprepitant SPC 150mg/Vial for Injection</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em><u>Diltiazem</u></em></strong></p><p>Interaction studies with fosaprepitant 150 mg and diltiazem have not been conducted; however, the following study with 100 mg of fosaprepitant should be considered when using Fosaprepitant SPC 150mg/Vial for Injection diltiazem. In patients with mild to moderate hypertension, infusion of 100 mg of fosaprepitant over 15 minutes with diltiazem 120 mg 3 times daily, resulted in a 1.4-fold increase in diltiazem AUC and a small but clinically meaningful decrease in blood pressure, but did not result in a clinically meaningful change in heart rate, or PR interval.</p><p>&nbsp;</p><p><strong><em><u>Induction</u></em></strong></p><p>The fosaprepitant 150 mg single dose did not induce CYP3A4 on Days 1 and 4 in the midazolam interaction study. It is anticipated that Fosaprepitant SPC 150mg/Vial for Injection would cause less or no greater induction of CYP2C9, CYP3A4, and glucuronidation than that caused by the administration of the 3-day oral aprepitant regimen, for which a transient induction with its maximum effect 6-8 days after first aprepitant dose has been observed. The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with Fosaprepitant Dimeglumine SPC 150mg/Vial Powder for solution for infusion.</p><p>&nbsp;</p><p><strong><em><u>Warfarin</u></em></strong></p><p>In patients on chronic warfarin therapy, the prothrombin time (INR) should be monitored closely during treatment with and for 14 days following the use of Fosaprepitant SPC 150mg/Vial for Injection for the prevention of chemotherapy induced nausea and vomiting (see section 4.4).</p><p>&nbsp;</p><p><strong><em><u>Hormonal contraceptives</u></em></strong></p><p>The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant. Alternative non-hormonal back-up methods of contraception should be used during treatment with fosaprepitant and for 2 months following the use of fosaprepitant.</p><p>&nbsp;</p><p><strong><em><u>5-HT3 antagonists</u></em></strong></p><p>Interaction studies with fosaprepitant 150 mg and 5-HT3 antagonists have not been conducted; however, in clinical interaction studies, the oral aprepitant regimen did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron). Therefore, there is no evidence of interaction with the use of Fosaprepitant SPC 150mg/Vial Powder for solution for infusion and 5-HT3 antagonists.</p><p><u>Effect of other medicinal products on the pharmacokinetics of aprepitant resulting from administration of fosaprepitant 150 mg</u></p><p>Concomitant administration of fosaprepitant with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result in several-fold increased plasma concentrations of aprepitant (see section 4.4). Ketoconazole increased the terminal half-life of oral aprepitant about 3-fold.</p><p>&nbsp;</p><p>Concomitant administration of fosaprepitant with active substances that strongly induce CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination could result in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy. Concomitant administration of fosaprepitant with herbal preparations containing St. John&#39;s Wort (<em>Hypericum perforatum</em>) is not recommended. Rifampicin decreased the mean terminal half-life of oral aprepitant by 68 %.</p><p>&nbsp;</p><p><strong><em><u>Diltiazem</u></em></strong></p><p>Interaction studies with fosaprepitant 150 mg and diltiazem have not been conducted; however, the following study with 100 mg of fosaprepitant should be considered when using Fosaprepitant SPC 150mg/Vial for Injection with diltiazem. Infusion of 100 mg fosaprepitant over 15 minutes with diltiazem 120 mg 3 times daily, resulted in a 1.5-fold increase of aprepitant AUC. This effect was not considered clinically important.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Paediatric population</u></em></strong></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Contraception in males and females</u></em></strong></p><p>The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant. Alternative non-hormonal back-up methods of contraception should be used during treatment with fosaprepitant and for 2 months following the last dose of fosaprepitant (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Pregnancy</u></em></strong></p><p>For fosaprepitant and prepatent no clinical data on exposed pregnancies are available. The potential for reproductive toxicities of fosaprepitant and prepatent have been not fully characterized, since exposure levels above the therapeutic exposure in humans could not be attained in animal studies. These studies did not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). The potential effects on reproduction of alterations in neurokinin regulation are unknown. Fosaprepitant SPC 150mg/Vial for Injection should not be used during pregnancy unless clearly necessary.</p><p>&nbsp;</p><p><strong><em><u>Breast-feeding</u></em></strong></p><p>Aprepitant is excreted in the milk of lactating rats after intravenous administration of fosaprepitant as well as after oral administration of aprepitant<strong>. </strong>It is not known whether aprepitant is excreted in human milk. Therefore, breast-feeding is not recommended during treatment with Fosaprepitant SPC 150mg/Vial for Injection</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Fertility</u></em></strong></p><p>The potential for effects of fosaprepitant and aprepitant on fertility has not been fully characterised because exposure levels above the therapeutic exposure in humans could not be attained in animal studies. These fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosaprepitant SPC 150mg/Vial for Injection may have minor influence on the ability to drive and use machines. Dizziness and fatigue may occur following administration of Fosaprepitant SPC 150mg/Vial for Injection (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Summary of the safety profile</u></em></strong></p><p>In clinical studies, various formulations of fosaprepitant have been administered to a total of 2,687 adults including 371 healthy subjects and 2,084 patients, and 199 children and adolescents with chemotherapy induced nausea and vomiting (CINV). Since fosaprepitant is converted to aprepitant, those adverse reactions associated with aprepitant are expected to occur with fosaprepitant. The safety profile of aprepitant was evaluated in approximately 6,500 adults and 184 children and adolescents.</p><p>&nbsp;</p><p><strong><em><u>Oral aprepitant</u></em></strong></p><p>The most common adverse reactions reported at a greater incidence in adults treated with the aprepitant regimen than with standard therapy in patients receiving HEC were: hiccups (4.6 % versus 2.9 %), alanine aminotransferase (ALT) increased (2.8 % versus 1.1 %), dyspepsia (2.6 % versus 2.0%), constipation (2.4 % versus 2.0 %), headache (2.0 % versus 1.8 %), and decreased appetite (2.0 % versus 0.5 %). The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving MEC was fatigue (1.4 % versus 0.9 %).</p><p>The most common adverse reactions reported at a greater incidence in paediatric patients treated with the aprepitant regimen than with the control regimen while receiving emetogenic cancer chemotherapy were hiccups (3.3 % versus 0.0 %) and flushing (1.1 % versus 0.0 %).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions - aprepitant</u></p><p>The following adverse reactions were observed in a pooled analysis of the HEC and MEC studies at a greater incidence with oral aprepitant than with standard therapy or in postmarketing use:</p><p>The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table. Some less common ADRs in the adult population were not observed in the paediatric studies.</p><p>Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>System organ class</p></td><td><p>Adverse reaction</p></td><td colspan="2"><p>Frequency</p></td></tr><tr><td><p>Infection and infestations</p></td><td><p>candidiasis, staphylococcal infection</p></td><td colspan="2"><p>rare</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>febrile neutropenia, anemia</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>hypersensitivity reactions including anaphylactic reactions</p></td><td colspan="2"><p>not known</p></td></tr><tr><td rowspan="2"><p>Metabolism and nutrition disorders</p></td><td><p>decreased appetite</p></td><td colspan="2"><p>common</p></td></tr><tr><td><p>polydipsia</p></td><td colspan="2"><p>rare</p></td></tr><tr><td rowspan="2"><p>Psychiatric disorders</p></td><td><p>anxiety</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>disorientation, euphoric mood</p></td><td colspan="2"><p>rare</p></td></tr><tr><td rowspan="3"><p>Nervous system disorders</p></td><td><p>headache</p></td><td colspan="2"><p>common</p></td></tr><tr><td><p>dizziness, somnolence</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>Cognitive disorder, lethargy, dysgeusia</p></td><td colspan="2"><p>rare</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>conjunctivitis</p></td><td colspan="2"><p>rare</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>Tinnitus</p></td><td colspan="2"><p>rare</p></td></tr><tr><td rowspan="2"><p>&nbsp;</p><p>Cardiac disorders</p></td><td><p>Palpitations</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>bradycardia, cardiovascular disorder</p></td><td colspan="2"><p>rare</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>hot flush</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td rowspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>hiccups</p></td><td colspan="2"><p>common</p></td></tr><tr><td><p>oropharyngeal pain, sneezing, cough, postnasal drip, throat irritation</p></td><td colspan="2"><p>rare</p></td></tr><tr><td rowspan="3"><p>&nbsp;</p><p>Gastrointestinal disorders</p></td><td><p>constipation, dyspepsia</p></td><td colspan="2"><p>common</p></td></tr><tr><td><p>eructation, nausea*, vomiting*, gastroesophageal reflux disease, abdominal pain, dry mouth, flatulence</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>duodenal ulcer perforation, stomatitis, abdominal distension, faeces hard, neutropenic colitis</p></td><td colspan="2"><p>rare</p></td></tr><tr><td rowspan="3"><p>Skin and subcutaneous tissue disorders</p></td><td><p>rash, acne</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>photosensitivity reaction, hyperhidrosis, seborrhoea, skin lesion, rash pruritic, Stevens- Johnson syndrome/toxic epidermal necrolysis</p></td><td colspan="2"><p>rare</p></td></tr><tr><td><p>pruritus, urticaria</p></td><td colspan="2"><p>not known</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>muscular weakness, muscle spasms</p></td><td colspan="2"><p>rare</p></td></tr><tr><td rowspan="2"><p>Renal and urinary disorders</p></td><td><p>dysuria</p></td><td colspan="2"><p>uncommon</p></td></tr><tr><td><p>pollakiuria</p></td><td colspan="2"><p>rare</p></td></tr><tr><td><p>General disorders and</p></td><td><p>fatigue</p></td><td colspan="2"><p>common</p></td></tr><tr><td rowspan="2"><p>administration site conditions</p></td><td><p>asthaenia, malaise</p></td><td><p>uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>oedema, chest discomfort, gait disturbance</p></td><td><p>rare</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p>Investigations</p></td><td><p>ALT increased</p></td><td><p>common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>AST increased; blood alkaline phosphatase increased</p></td><td><p>uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased</p></td><td><p>rare</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>*Nausea and vomiting were efficacy parameters in the first 5-days of post-chemotherapy treatment&nbsp; and were reported as adverse reactions only thereafter.</p><p>&nbsp;</p><p><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p>The adverse reactions profiles in the Multiple-Cycle extension of HEC and MEC studies for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1.</p><p>In an additional active-controlled clinical study in 1,169 patients receiving aprepitant and HEC, the adverse reactions profile was generally similar to that seen in the other HEC studies with aprepitant.</p><p>Additional adverse reactions were observed in patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, tomach discomfort, sub-ileus*, visual acuity reduced, wheezing.</p><p>*Reported in patients taking a higher dose of aprepitant.</p><p>&nbsp;</p><p><strong><em><u>Fosaprepitant</u></em></strong></p><p>In an active-controlled clinical study in patients receiving HEC, safety was evaluated for 1,143 patients receiving the 1-day regimen of Fosaprepitant SPC 150mg/Vial for Injection compared to 1,169 patients receiving the 3-day regimen of aprepitant. Additionally, in a placebo- controlled clinical trial in patients receiving MEC, safety was evaluated for 504 patients receiving a single dose of Fosaprepitant SPC 150mg/Vial for Injection compared to 497 patients receiving the control regimen</p><p>In a pooled analysis of 3 active-controlled clinical studies in paediatric patients (aged 6 months to 17 years) receiving either HEC or MEC and a single dose of Fosaprepitant SPC 150mg/Vial for Injection at or above the recommended 1-day regimen dose, safety was evaluated for 139 patients receiving the 1-day regimen of Fosaprepitant SPC 150mg/Vial for Injection In the same analysis, safety was evaluated for 199 patients receiving either HEC or MEC and a single dose of Fosaprepitant SPC 150mg/Vial for Injection at or above the recommended 3-day regimen of Fosaprepitant SPC 150mg/Vial for Injection. Safety data following the administration of the 3-day IV/oral/oral regimen were also included.</p><p>No data are available following the administration of a 3-day IV fosaprepitant regimen in paediatric patients. The safety profile of the 3-day IV fosaprepitant regimen in paediatric patients is expected to be similar to that of the 1-day fosaprepitant regimen as the low daily through levels do not significantly increase the exposures on subsequent days.</p><p>The safety profile was generally similar to that seen in the aprepitant table above.</p><p>&nbsp;</p><p><strong><em><u>Tabulated list of adverse reactions - fosaprepitant</u></em></strong></p><p>The following are adverse reactions reported in patients receiving fosaprepitant in clinical studies or postmarketing that have not been reported with aprepitant as described above: The frequency categories in the table are based on studies in adults; the observed frequencies in the paediatric studies were similar or lower. Some adverse reactions that are commonly observed in the adult population were not observed in the paediatric studies.</p><p>Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>System organ class</p></td><td><p>Adverse reaction</p></td><td><p>Frequency</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>flushing, thrombophlebitis (predominantly, infusion-site thrombophlebitis)</p></td><td><p>uncommon</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>erythema</p></td><td><p>uncommon</p></td></tr><tr><td rowspan="3"><p>&nbsp;</p><p>General disorders and administration site conditions</p></td><td><p>infusion site erythema, infusion site pain, infusion site pruritus</p></td><td><p>uncommon</p></td></tr><tr><td><p>infusion site induration</p></td><td><p>rare</p></td></tr><tr><td><p>immediate hypersensitivity reactions including flushing, erythema, dyspnea, anaphylactic reactions/anaphylactic shock</p></td><td><p>not known</p></td></tr><tr><td><p>Investigations</p></td><td><p>blood pressure increased</p></td><td><p>uncommon</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em><u>Reporting of suspected adverse reactions</u></em></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, fosaprepitant should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of aprepitant, emesis induced by a medicinal product may not be effective.</p><p>Aprepitant cannot be removed by haemodialysis</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiemetics and antinauseants, ATC code: A04AD12.</p><p>Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant (see section 5.2). The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out. Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors. The pharmacological effect of fosaprepitant is attributed to aprepitant</p><p>1-Day Regimen of Fosaprepitant in Adults</p><p><u>Highly Emetogenic Chemotherapy (HEC)</u></p><p>In a randomized, parallel, double-blind, active-controlled study, Fosaprepitant SPC 150mg/Vial for Injection (N=1,147) was compared with a 3-day aprepitant regimen (N=1,175) in adult patients receiving a HEC regimen that included cisplatin (&ge;70 mg/m2). The fosaprepitant regimen consisted of fosaprepitant 150 mg on Day 1 in combination with ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg on Day 1, 8 mg on Day 2, and 8 mg twice daily on Days 3 and 4. The aprepitant regimen consisted of aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 and 3 in combination with ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg on Day 1 and 8 mg daily on Days 2 through 4. Fosaprepitant placebo, aprepitant placebo, and dexamethasone placebo (in the evenings on Days 3 and 4) were used to maintain blinding (see section 4.2). Although a 32 mg intravenous dose of ondansetron was used in clinical trials, this is no longer the recommended dose. See the product information for the selected 5-HT3 antagonist for appropriate dosing information.</p><p>&nbsp;</p><p>Efficacy was based on evaluation of the following composite measures: complete response in both the overall and delayed phases and no vomiting in the overall phase. Fosaprepitant SPC 150mg/Vial for Injection on was shown to be noninferior to that of the 3day regimen of aprepitant. A summary of the primary and secondary endpoints is shown in Table 1.</p><p><img alt="" width="649" height="280" src="data:image/png;base64,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" /></p><p>*Primary end point is bolded.</p><p>**N: Number of patients included in the primary analysis of complete response.</p><p>&dagger;Difference and confidence interval (CI) were calculated using the method proposed by Miettinen and Nurminen and adjusted for Gender.</p><p>&Dagger;Complete response = no vomiting and no use of rescue therapy.</p><p>&sect;Overall = 0 to 120 hours postinitiation of cisplatin chemotherapy.</p><p>&sect;&sect;Delayed phase = 25 to 120 hours postinitiation of cisplatin chemotherapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>Moderately Emetogenic Chemotherapy (MEC)</p><p>In a randomized, parallel, double-blind, placebo-controlled study, Fosaprepitant SPC 150mg/Vial for Injection (N=502) in combination with ondansetron and dexamethasone was compared with ondansetron and dexamethasone alone (control regimen) (N=498) in adult patients receiving a moderately emetogenic chemotherapy regimen. The fosaprepitant regimen consisted of fosaprepitant 150 mg on Day 1 in combination with oral ondansetron 8 mg for 2 doses and oral dexamethasone 12 mg. On Days 2 and 3, patients in the fosaprepitant group received placebo for ondansetron every 12 hours. The control regimen onsisted of fosaprepitant placebo 150 mg IV on Day 1 in combination with oral ondansetron 8 mg for 2 doses.</p><p>and oral dexamethasone 20 mg. On Days 2 and 3, patients in the control group received 8 mg oral ondansetron every 12 hours. Fosaprepitant placebo and dexamethasone placebo (on Day 1) were used to maintain blinding.</p><p>The efficacy of fosaprepitant was evaluated based on the primary and secondary endpoints listed in Table 2 and was shown to be superior to the control regimen with regard to complete response in the delayed and overall phases.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p>Table 4</p></td></tr><tr><td colspan="4"><p>Percent of adult patients receiving Moderately Emetogenic Chemotherapy responding by treatment group and phase</p></td></tr><tr><td><p>ENDPOINTS*</p></td><td><p>Fosaprepitant regimen</p><p>(N =502) ** %</p></td><td><p>Control regimen</p><p>(N =498) ** %</p></td><td><p>P-Value</p></td></tr><tr><td colspan="4"><p>Complete response&dagger;</p></td></tr><tr><td><p>Delayed phase&Dagger;</p></td><td><p>78.9</p></td><td><p>68.5</p></td><td><p>&lt;0.001</p></td></tr><tr><td colspan="4"><p>Com66.9plete response&dagger;</p></td></tr><tr><td><p>Overall&sect;</p></td><td><p>77.1</p></td><td><p>66.9</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Acute phase&sect;&sect;</p></td><td><p>93.2</p></td><td><p>91</p></td><td><p>0.18</p></td></tr></tbody></table><p>&nbsp;</p><p>*Primary endpoint is bolded.</p><p>**N: Number of adult patients included in the intention to treat population.</p><p>&dagger; Complete response = no vomiting and no use of rescue therapy.</p><p>&Dagger; Delayed phase = 25 to 120 hours post-initiation of chemotherapy.</p><p>&sect;Overall = 0 to 120 hours post-initiation of chemotherapy.</p><p>&sect;&sect;Acute= 0 to 24 hours post-initiation of chemotherapy.</p><p>&nbsp;</p><p>The estimated time to first emesis is depicted by the Kaplan Meier plot in Figure 1. Figure 1</p><p>Percent of patients receiving Moderately Emetogenic Chemotherapy who remain emesis free over time</p><p><img alt="" width="424" height="241" src="data:image/jpeg;base64,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" /></p><p><strong><em><u>Paediatric population</u></em></strong></p><p>In 3 active-controlled, open-label clinical studies, paediatric patients aged 6 months to 17 years received either highly or moderately emetogenic chemotherapy and a single dose of fosaprepitant at or above the recommended 1-day regimen dose (139 patients) or 3-day regimen (199 patients), in combination with ondansetron with or without dexamethasone.</p><p>&nbsp;</p><p><u>Paediatric Patients Receiving 1-Day Fosaprepitant Regimen </u></p><p>The efficacy of the 1-day fosaprepitant regimen in paediatric patients was extrapolated from that demonstrated in adults receiving the 1-day fosaprepitant regimen as described in the 1-Day Regimen of Fosaprepitant in Adults subsection.</p><p>The efficacy of a 1-day fosaprepitant regimen in paediatric patients is expected to be similar to that of the 1-day adult fosaprepitant regimen.</p><p>&nbsp;</p><p><strong><em><u>Paediatric Patients Receiving 3-Day Fosaprepitant Regimen</u></em></strong></p><p>The efficacy of the 3-day fosaprepitant regimen in paediatric patients was based on that demonstrated in paediatric mpatients receiving the 3-day oral aprepitant regimen.</p><p>The efficacy of a 3-day fosaprepitant regimen in paediatric patients is expected to be similar to that of the 3-day oral aprepitant regimen. See the summary of product characteristics for Fosaprepitant capsules and Fosaprepitant powder for oral suspension for complete clinical information regarding studies performed with oral aprepitant.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosaprepitant, a prodrug of aprepitant, when administered intravenously is rapidly converted to aprepitant. Plasma concentrations of fosaprepitant are below quantifiable levels within 30 minutes of the completion of infusion.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em><u>Aprepitant after fosaprepitant administration</u></em></strong></p><p>Following a single intravenous 150-mg dose of fosaprepitant administered as a 20-minute infusion to healthy volunteers, the mean AUC0-&infin; of aprepitant was 35.0 &micro;g&bull;hr/ml and the mean maximal aprepitant concentration was 4.01 &micro;g/ml.</p><p>&nbsp;</p><p><strong><em><u>Distribution</u></em></strong></p><p>Aprepitant is highly protein bound, with a mean of 97 %. The geometric mean volume of distribution at steady state (Vdss) of aprepitant estimated from a single 150 mg intravenous dose of fosaprepitant is approximately 82 l in humans.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em><u>Biotransformation</u></em></strong></p><p>Fosaprepitant was rapidly converted to aprepitant in <em>in vitro </em>incubations with liver preparations from humans. Furthermore, fosaprepitant underwent rapid and nearly complete conversion to aprepitant in S9 preparations from other human tissues including kidney, lung and ileum. Thus, it appears that the conversion of fosaprepitant to aprepitant can occur in multiple tissues. In humans, fosaprepitant administered intravenously was rapidly converted to aprepitant within 30 minutes following the end of infusion.</p><p>&nbsp;</p><p>Aprepitant undergoes extensive metabolism. In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100 mg dose of [14C]- fosaprepitant, a prodrug for aprepitant, indicating a substantial presence of metabolites in the plasma. Twelve metabolites of aprepitant have been identified in human plasma. The metabolism of aprepitant occurs largely via oxidation at the morpholine ring and its side chains and the resultant metabolites were only weakly active. <em>In vitro </em>studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.</p><p>&nbsp;</p><p>All metabolites observed in urine, faeces and plasma following an intravenous 100 mg [14C]- fosaprepitant dose were also observed following an oral dose of [14C]-aprepitant. Upon conversion of 245.3 mg of fosaprepitant dimeglumine (equivalent to 150 mg fosaprepitant) to aprepitant, 23.9 mg of phosphoric acid and 95.3 mg of meglumine are liberated.</p><p>&nbsp;</p><p><strong><em><u>Elimination</u></em></strong></p><p>Aprepitant is not excreted unchanged in urine. Metabolites are excreted in urine and via biliary excretion in faeces. Following a single intravenously administered 100 mg dose of [14C]- fosaprepitant to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.</p><p>&nbsp;</p><p>The pharmacokinetics of aprepitant is non-linear across the clinical dose range. The terminal half-life of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 11 hours. The geometric mean plasma clearance of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 73 ml/min.</p><p>&nbsp;</p><p><strong><em><u>Pharmacokinetics in special populations</u></em></strong></p><p><em>Hepatic impairment: </em>Fosaprepitant is metabolized in various extrahepatic tissues; therefore, hepatic impairment is not expected to alter the conversion of fosaprepitant to aprepitant. Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent. No dose adjustment is necessary for patients with mild hepatic impairment. Conclusions regarding the influence of moderate hepatic impairment (Child-Pugh class B) on aprepitant pharmacokinetics cannot be drawn from available data. There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C).</p><p>&nbsp;</p><p><em>Renal impairment: </em>A single 240 mg dose of oral aprepitant was administered to patients with severe renal impairment (CrCl&lt; 30 ml/min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.</p><p>&nbsp;</p><p>In patients with severe renal impairment, the AUC 0-&infin;of total aprepitant (unbound and protein bound) decreased by 21 % and Cmax decreased by 32 %, relative to healthy subjects. In patients with ESRD undergoing haemodialysis, the AUC0-&infin; of total aprepitant decreased by 42 % and Cmax decreased by 32 %. Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound aprepitant was not significantly affected in patients with renal impairment compared with healthy subjects. Haemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2 % of the dose was recovered in the dialysate.</p><p>No dose adjustment is necessary for patients with renal impairment or for patients with ESRD undergoing haemodialysis.</p><p>Paediatric population: As part of a 3-day IV/IV/IV regimen, simulated median AUC0-24hr of aprepitant with median peak plasma concentration (Cmax) on Day 1 and the median concentrations at the end of Day 1, Day 2 and Day 3 in paediatric patients (6 months to 17 years old) are shown in Table 5.</p><p>Table 5:</p><p>Pharmacokinetic parameters of aprepitant for 3-day IV fosaprepitant regimen in paediatric patients</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Population</p></td><td><p>3-day IV/IV/IV</p><p>dose</p></td><td><p>AUC 0-24 hr.</p><p>(ng*hr/mL)</p></td><td><p>Cmax (ng/mL)</p></td><td><p>C24</p><p>(ng/mL)</p></td><td><p>C48</p><p>(ng/mL)</p></td><td><p>C72</p><p>(ng/mL)</p></td></tr><tr><td><p>12 - 17 years old</p></td><td><p>115mg, 80mg, 80mg</p></td><td><p>21172</p></td><td><p>2475</p></td><td><p>454</p></td><td><p>424</p></td><td><p>417</p></td></tr><tr><td><p>6 - &lt; 12</p><p>years old</p></td><td rowspan="3"><p>3mg/kg, 2mg/kg, 2mg/kg</p></td><td><p>25901</p></td><td><p>2719</p></td><td><p>518</p></td><td><p>438</p></td><td><p>418</p></td></tr><tr><td><p>2 - &lt; 6 years old</p></td><td><p>20568</p></td><td><p>2335</p></td><td><p>336</p></td><td><p>248</p></td><td><p>232</p></td></tr><tr><td><p>6 months &ndash;</p><p>&lt; 2 years old</p></td><td><p>16979</p></td><td><p>1916</p></td><td><p>256</p></td><td><p>179</p></td><td><p>167</p></td></tr></tbody></table><p>&nbsp;</p><p>In the 1-day IV fosaprepitant setting, simulated median AUC0-24hr of aprepitant with median peak plasma concentration (Cmax) on Day 1 and the median concentrations at the end of Day 1, Day 2 and Day 3 in paediatric patients (6 months to &lt; 12 years old) and observed mean AUC0-24hr with median peak plasma concentration (Cmax) on Day 1 and mean concentrations at the end of Day 1, Day 2 and Day 3 in paediatric patients (12 to 17 years old) are shown in Table 6</p><p>Table 6: Pharmacokinetic parameters of aprepitant for 1-day IV fosaprepitant regimen in paediatric patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Population</p></td><td><p>1-day IV dose</p></td><td><p>AUC 0-24 hr.</p><p>(ng*hr/mL)</p></td><td><p>Cmax (ng/mL)</p></td><td><p>C24</p><p>(ng/mL)</p></td><td><p>C48</p><p>(ng/mL)</p></td><td><p>C72</p><p>(ng/mL)</p></td></tr><tr><td><p>12 - 17 years old</p></td><td><p>150mg,</p></td><td><p>30400</p></td><td><p>3500</p></td><td><p>735</p></td><td><p>NR*</p></td><td><p>NR*</p></td></tr><tr><td><p>6 - &lt; 12</p><p>years old</p></td><td rowspan="2"><p>4mg/kg,</p></td><td><p>35766</p></td><td><p>3637</p></td><td><p>746</p></td><td><p>227</p></td><td><p>69.2</p></td></tr><tr><td><p>2 - &lt; 6 years old</p></td><td><p>28655</p></td><td><p>3150</p></td><td><p>494</p></td><td><p>108</p></td><td><p>23.5</p></td></tr><tr><td><p>6 months &ndash;</p><p>&lt; 2 years old</p></td><td><p>5 mg/kg</p></td><td><p>30484</p></td><td><p>3191</p></td><td><p>522</p></td><td><p>112</p></td><td><p>24.4</p></td></tr></tbody></table><p>&nbsp;</p><p>*NR = Not Reported</p><p>A population pharmacokinetic analysis of aprepitant in paediatric patients (aged 6 months through 17 years) suggests that gender and race have no clinically meaningful effect on the pharmacokinetics of aprepitant.</p><p><strong><em><u>Relationship between concentration and effect</u></em></strong></p><p>Positron emission tomography (PET) imaging studies, using a highly specific NK1-receptor tracer, in healthy young men administered a single intravenous dose of 150 mg fosaprepitant (N=8) demonstrated brain NK1 receptor occupancy of &ge;100 % at Tmax, and 24 hours, &ge;97 % at 48 hours, and between 41 % and 75 % at 120 hours, following dosing. Occupancy of brain NK1 receptors, in this study, correlate well with aprepitant plasma concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre-clinical data obtained with intravenous administration of fosaprepitant and oral administration of aprepitant reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, genotoxicity (including <em>in vitro </em>tests), and toxicity to reproduction and development.</p><p>Carcinogenic potential in rodents was only investigated with orally administered aprepitant. However, it should be noted that the value of the toxicity studies carried out with rodents, rabbits and monkeys, including the reproduction toxicity studies, are limited since systemic exposures to fosaprepitant and aprepitant were only similar or even lower than therapeutic exposure in adult humans. In the performed safety pharmacology and repeated dose toxicity studies with dogs, fosaprepitant Cmax and aprepitant AUC values were up to 3 times and 40 times, respectively, higher than clinical values.</p><p>&nbsp;</p><p>In a toxicity study in juvenile dogs treated with fosaprepitant from postnatal day 14 to day 42, a decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and oedema of vaginal tissues were seen in females from 4 mg/kg/day. In a juvenile toxicity study in rats treated with aprepitant from postnatal day 10 to day 63, earlier vaginal opening in females from 250 mg/kg b.i.d. And delayed preputial separation in males from 10 mg/kg b.i.d was seen. There were no treatment-related effects on mating, fertility or embryonic/foetal survival, and no pathological changes in the reproductive organs. There were no margins to clinically relevant exposure of aprepitant. For short term treatment, these findings are considered unlikely to be clinically relevant.</p><p>In laboratory animals, fosaprepitant in non-commercial formulations caused vascular toxicity and hemolysis at concentrations below 1 mg/ml and higher, dependent on the formulation. In human washed blood cells also evidence of hemolysis was found with non-commercial formulations at fosaprepitant concentrations of 2.3 mg/ml and higher, although tests in human whole blood were negative. No hemolysis was found with the commercial formulation up to a fosaprepitant concentration of 1 mg/ml in human whole blood and washed human erythrocytes.</p><p>In rabbits, fosaprepitant caused initial transient local acute inflammation following paravenous, subcutaneous and intramuscular administration. At the end of the follow-up period (post-dose day 8), up to slight local subacute inflammation was noted following paravenous and intramuscular administration and additional up to moderate focal muscle degeneration/necrosis with muscle regeneration following intramuscular administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium edetate, Polysorbate 80, Lactose anhydrous, Sodium hydroxide Pellets, Hydrochloric acid and Water for Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosaprepitant SPC 150mg/Vial for Injection is incompatible with any solutions containing divalent cations (e.g., Ca2+, Mg2+), including Hartman&#39;s and lactated Ringer&#39;s solutions. This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
After reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 mL Type-1 clear tubular glass vial with 13 mm neck containing Fosaprepitant Dimeglumine for</p><p>Injection 150 mg/ vial in lyophilized cake or powder form is stoppered with 13 mm Bromo butyl</p><p>double slotted rubber stopper sealed with 13 mm aluminium flip off seal with Green color plastic disc.</p><p><strong>Pack sizes:</strong> 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosaprepitant SPC 150mg/Vial for Injection must be reconstituted and then diluted prior to administration.</p><p>Preparation of Fosaprepitant SPC 150mg/Vial for Injection for intravenous administration:</p><p>1.&nbsp; Inject 5 ml sodium chloride 9 mg/ml (0.9 %) solution for injection into the vial. Assure that sodium chloride 9 mg/ml (0.9 %) solution for injection is added to the vial along the vial wall in order to prevent foaming. Swirl the vial gently. Avoid shaking and jetting sodium chloride 9 mg/ml (0.9 %) solution for injection into the vial.</p><p>2.&nbsp; Prepare an infusion bag filled with 145 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection (for example, by removing 105 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection from a 250 ml sodium chloride 9 mg/ml (0.9 %) solution for injection infusion bag)..</p><p>3.&nbsp; Withdraw the entire volume from the vial and transfer it into an infusion bag containing 145 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection to yield a total volume of 150 ml. Gently invert the bag 2-3 times.</p><p>4.&nbsp; Determine the volume to be administered from this prepared infusion bag, based on the recommended dose (see section 4.2).</p><p><strong><em><u>Adults</u></em></strong></p><p>The entire volume of the prepared infusion bag (150 ml) should be administered. <u>Paediatrics</u></p><p>In patients 12 years and older, the volume to be administered is calculated as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Volume to administer (ml) equals the recommended dose (mg)</p><p>In patients 6 months to less than 12 years, the volume to be administered is calculated as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Volume to administer (ml) = recommended dose (mg/kg) x weight (kg) o Note: Do not exceed maximum doses (see section 4.2).</p><p>5.&nbsp; If necessary, for volumes less than 150 ml, the calculated volume can be transferred to an appropriate size bag or syringe prior to administration by infusion.</p><p>The appearance of the reconstituted solution is the same as the appearance of the diluent.</p><p>The reconstituted and diluted medicinal product should be inspected visually for particulate matter and discoloration before administration.</p><p>Discard any remaining solution and waste material. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>The medicinal product must not be reconstituted or mixed with solutions for which physical and chemical compatibility has not been established (see section 6.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad road, Building 911- The First Round
Riyadh, Saudi Arabia
Tel: +966-11-92001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 19047 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb. 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>